Phase 4 N=51 Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty
Osteoporosis
Primary: Bone Mineral Density (BMD) — -3.97; 14.30; -27.3; -9.58 Percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=92 Does Propranolol Attenuate Inflammatory Responses to a Psychological Stressor?
Stress, Psychological · Inflammation · Cortisol
Primary: Change in Interleukin-6 (IL-6) — .05; .16; .31; .24 log(picograms/mL)
Phase 4 N=40 Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
Diabetic Macular Edema
Primary: A Change Between Two Time Points is Reported for Maximum Reading Speed — 161.94; 167.65 words per minute
Phase 4 N=22 Targeting the Right Ventricle in Pulmonary Hypertension
Pulmonary Hypertension
Primary: Changes in Right Ventricular Ejection Fraction — 5.8; -4.7; 0.49 percentage
Phase 4 N=27 Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection
Leukemia · Lymphoma · Blood Disorders
Primary: Length of Stay (LOS) in Those With 14 Confirmed Catheter Related Infection Cases — 124; 208 HOURS
Phase 4 N=179 Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
Encephalitis, Tick-Borne
Primary: Seropositivity Rate Measured by Neutralization Test (NT) at 21-35 Days After the First Tick-borne Encephalitis (TBE) Booster Vaccination in Study 700401 — 100.0…
Phase 4 N=103 The Use of Probiotics to Evaluate Colonization With Antimicrobial Resistant Bacteria
Infectious Disease of Digestive Tract
Primary: Number of Participants With Combination of Gastrointestinal Tract Colonization With Multi-drug Resistant Gram-negative Bacteria, C. Difficile and VRE — 8; 8 Participants
Phase 4 N=60 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Carcinoma, Non-Small-Cell Lung
Primary: Objective Tumour Response (Complete Response [CR], Partial Response [PR]) as Assessed by the Investigator According to the RECIST Version 1.1 — 50 Percentage of…
Phase 4 N=240 Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
Influenza · Flu
Primary: Number of Participants Reporting Solicited Injection Site (Tenderness/Pain, Erythema, Swelling) and Systemic Reactions (Fever, Vomiting, Crying Abnormal, Drowsiness…
Phase 4 N=115 Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years
Turner's Syndrome
Primary: Height SDS at Year 4 — -1.35; -2.44 standard deviation score
Phase 4 N=28 Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
Influenza
Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants
Phase 4 N=33 Acamprosate vs. Placebo in Bipolar Alcoholics
Alcohol Dependence · Bipolar Disorder
Primary: Time to First Drink (Days) — 16.5; 8.0 Days
Phase 4 N=152 The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease
GERD Gastroesophageal Reflux Disease
Primary: Elimination of Moderate-severe Regurgitation at 6 Months — 10; 42 Participants
Phase 4 N=20 The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
Influenza
Primary: Change in Geometric Mean Serum Hemagglutination Inhibition (HAI) Antibody Titer — 23; 56.5; 188; 108 HAI antibody Titers
Phase 4 N=86 Clinical Comparison of Femoral Nerve Versus Adductor Canal Block Following Anterior Ligament Reconstruction
Anterior Cruciate Ligament Injury
Primary: Quadriceps Muscle Activation as Assessed by Surface Electromyography (sEMG) — 266.5; 212.5 microvolts (uV)